Former world number one tennis player,Maria Sharapova, has failed a drug test for Meldonium on January 26, 2016.
Meldonium (also known as Mildronate) is manufactured in Latvia, at the Institute of Organic Synthesis and used in the treatment of certain heart conditions. It works by dilating blood vessels and increasing blood flow, which in turn improves exercise capacity, physical and mental endurance, and also brain function. It significantly improves patients’ mood. They become more active, their motor dysfunction decreases, and asthenia (abnormal physical weakness or lack of energy), dizziness and nausea become less pronounced.
Meldonium is Used to
According to rupharma.com, Mildronate comes in capsules; 40pills/pack, and a dosage of 250mg/pill, this is served per doctors order.
Meldonium was on the World Anti-Doping Agency’s (WADA) list of drugs being monitored until September 2015, when it was added to the list of banned substances, effective January 1, 2016.
Maria Sharapova had been taking Meldonium since 2006. Her family doctor had prescribed it for her irregular EKGs, magnesium deficiency, and a family history of diabetes.
Sharapova claims she was unaware Meldonium had been added to the WADA list of banned substances until receipt of a letter from the International Tennis Federation informing her of a failed drug test during the 2016 Australian Open.
Other athletes who have tested positive for the same drug is 33-year old Russian professional bicyclist Eduard Vorganov in February 2016.
See full text of substances banned by the World Anti-Doping Agency’s (WADA) here
Kobby Blay is the chief health editor at Ghanahealthnest.com. A professional practicing nurse with specialty in mental health and focus for health communications, public health, medical/documentary photography, ICT and systems perspective for health improvement.